Skip to Content

Generic Pliaglis Availability

Pliaglis is a brand name of lidocaine/tetracaine topical, approved by the FDA in the following formulation(s):

PLIAGLIS (lidocaine; tetracaine - cream;topical)

  • Manufacturer: TARO PHARMS
    Approval date: June 29, 2006
    Strength(s): 7%;7% [RLD]

Has a generic version of Pliaglis been approved?

An Authorized Generic version of Pliaglis has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • Lidocaine and Tetracaine TOPICAL CREAM 70; 70 mg/g; mg/g
    Innovida Pharmaceutique Corporation
    NDC Code: 718000631

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pliaglis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and apparatus for drug delivery involving phase changing formulations
    Patent 6,528,086
    Issued: March 4, 2003
    Inventor(s): Jie; Zhang
    Assignee(s): Zars, Inc.

    This invention relates to an apparatus and method of drug delivery on a human body surface. The formulation comprises a drug, a conversion agent capable of converting the formulation from a less solid phase to a coherent, soft, solid phase, and a vehicle medium or carrier for the drug and conversion agent. The drug formulation is applied to this human body surface in its less than solid phase and is subsequently converted to a soft solid phase while the drug is being delivered through the human body surface. After delivery of the drug is complete, the soft solid formulation can be removed or peeled from the body surface as a coherent solid formulation. The drug formulation provides control over drug delivery rates and allows the formulation to be removed without leaving a messy, residual formulation on the body surface.

    Patent expiration dates:

    • September 28, 2019
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Pliaglis (lidocaine / tetracaine topical)

Consumer resources

Other brands: Synera, S-Caine Peel

Professional resources

Related treatment guides

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.